Results 81 to 90 of about 14,877 (300)
Abciximab in the treatment of coronary artery disease
Reviews in Health Care, 2013 Antiplatelet therapy constitutes a cornerstone in the strategies aimed at the effective management of acute coronary syndrome. Abciximab is the oldest and most commonly used intravenous antiplatelet agent in this context, in particular when an invasive strategy is adopted. It is very commonly used in more unstable and high- risk patients.
Jayasinghe, Rohan +2 more
openaire +4 more sources
Advanced Science, Volume 11, Issue 26, July 10, 2024.This review describes and critically evaluates computational and biological models of atherosclerosis, focusing on the hemodynamics of occluded coronary arteries. It examines emerging strategies that integrate computational and biological models and explores the advances in imaging, biofabrication, single‐cell omics, and machine learning for model ...
Thao Nhu Anne Marie Vuong +8 more
wiley +1 more source
Journal of Tehran University Heart Center, 2015 Background: Administration of glycoprotein IIb/IIIa inhibitors is an effective adjunctive treatment strategy during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
MohammadHasan Namazi +5 more
doaj
Prophylaxis of Experimental Endocarditis With Antiplatelet and Antithrombin Agents: A Role for Long-term Prevention of Infective Endocarditis in Humans? [PDF]
, 2017 Background. Infective endocarditis (IE) mostly occurs after spontaneous low-grade bacteremia. Thus, IE cannot be prevented by circumstantial antibiotic prophylaxis.
Chaouch, Aziz +7 more
core
Primary Angioplasty in Women: Data from the Portuguese Registry of Interventional Cardiology [PDF]
, 2014 Objetivos: A mortalidade na mulher após angioplastia primária (ICP-P) é superior à do homem. Contudo, permanece contraditório o papel do sexo poder ser fator de risco independente para mortalidade no contexto de enfarte agudo do miocárdio com ...
Calé, R +4 more
core +1 more source
Journal of Peptide Science, Volume 30, Issue 7, July 2024.The development of highly affine, selective peptides and small molecules in recent years has allowed peptide drugs (PDCs) and small molecule–drug conjugates (SMDCs) to increasingly compete with antibody–drug conjugates (ADCs). This review summarises and describes integrin‐addressing PDCs and SMDCs, while highlighting points of great interest.
Jannik Paulus, Norbert Sewald
wiley +1 more source
Folia Histochemica et Cytobiologica, 2010 Abciximab (Abci) and eptifibatide (Epti) are antiaggregate drugs which may reduce thrombotic complications inacute coronary syndromes. The aim of this work was the investigation of the interaction between the phospholipid-GPIIb/IIIa glycoprotein complex ...
Ewa Gorodkiewicz +2 more
doaj
Biosensing materials for monoclonal antibody detection: An overview
Responsive Materials, Volume 2, Issue 2, May 2024.This article provides an overview of the recent advances and functional applications of biosensing materials for monoclonal antibody (mAb) detection. In the review, we present the approaches by which mAb receptors are combined with materials to construct responsive analytical platforms, enabling real‐time monitoring and diagnosis.
Yuxin Zhang +3 more
wiley +1 more source
Farmeconomia: Health Economics and Therapeutic Pathways, 2005 Inhibition of platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor prevents platelet aggregation by controlling its final common pathway, the cross-binding of fibrinogen, bridging across adjacent platelets.
Lorenzo Pradelli
doaj +1 more source
Angiographic findings in patients with refractory unstable angina according to troponin T status [PDF]
, 1999 BACKGROUND: The CAPTURE (C7E3 fab AntiPlatelet Therapy in Unstable REfactory angina) trial enrolled patients with refractory unstable angina and documented a therapeutic benefit for abciximab, a platelet glycoprotein IIb/IIIa receptor ...
Brand, M.J.B.M. (Marcel) van den +3 more
core